OXYCODONE Drug Interactions
Also known as: Oxycodone Hydrochloride
OXYCODONE (brand name: Oxycodone Hydrochloride) is a Opioid Analgesics. 1 INDICATIONS AND USAGE Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can…OXYCODONE has 17 documented drug interactions in our database, including 4 contraindicated, 13 major, 0 moderate, and 0 minor interactions.
4
Contraindicated
13
Major
0
Moderate
0
Minor
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased respiratory rate and depth, hypoxemia, somnolence, confusion, and impaired psychomotor function. The effects can be particularly pronounced in opioid-naive individuals or those with underlying respiratory conditions.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Clonazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS activity.
Clinical Management
Avoid concomitant use of oxycodone and clonazepam due to the high risk of severe adverse outcomes, as highlighted by the FDA Black Box Warning. If co-prescription is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, monitor patients closely for respiratory depression and sedation, and consider naloxone availability. Educate patients and caregivers on the risks and symptoms of respiratory depression.
The primary clinical effects include profound sedation, respiratory depression (leading to hypoventilation and apnea), hypotension, and psychomotor impairment. This can rapidly progress to coma and death due to respiratory arrest, particularly in opioid-naïve individuals or those with underlying respiratory conditions.
Mechanism
Oxycodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), causing CNS depression, analgesia, and respiratory depression. Alprazolam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS function.
Clinical Management
Concomitant use of oxycodone and alprazolam should be avoided due to the high risk of severe adverse outcomes, including death. If co-administration is absolutely necessary and no alternatives exist, prescribe the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone should be readily available.
The interaction can manifest as severe sedation, profound respiratory depression, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and hypoxia. These effects can be rapid in onset and life-threatening.
Mechanism
Oxycodone, an opioid agonist, and triazolam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Their co-administration leads to an additive or synergistic depression of the CNS, particularly affecting the medullary respiratory center, which can result in profound respiratory depression and hypoventilation.
Clinical Management
Concomitant use of opioids and benzodiazepines should be avoided due to the high risk of severe adverse outcomes, including respiratory depression and death. If no alternatives are available, prescribe the lowest effective doses and shortest possible duration, closely monitor patients for respiratory depression and sedation, and educate patients and caregivers on the risks. Consider naloxone availability.
This interaction leads to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The risk of overdose and fatal outcomes is significantly increased.
Mechanism
Oxycodone, an opioid agonist, and chlordiazepoxide hydrochloride, a benzodiazepine, both exert central nervous system (CNS) depressant effects by different mechanisms. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The concomitant use of these agents results in an additive and synergistic CNS depression.
Clinical Management
Concomitant use of oxycodone and chlordiazepoxide hydrochloride should be avoided due to the severe risks, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary and no alternatives are available, the lowest effective doses should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Patients and caregivers must be educated on the risks and symptoms, and naloxone should be prescribed for opioid overdose reversal.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening.
Mechanism
Both oxycodone, an opioid analgesic, and cyclobenzaprine, a skeletal muscle relaxant, exert central nervous system (CNS) depressant effects. This interaction is due to their additive pharmacological actions on various neurotransmitter systems, leading to enhanced CNS depression.
Clinical Management
Concomitant use should generally be avoided. If unavoidable, initiate with lower doses of one or both drugs, monitor patients closely for signs of respiratory depression and excessive sedation, and advise patients against driving or operating heavy machinery. Consider alternative therapies if possible.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Other effects include hypotension and increased risk of falls.
Mechanism
Oxycodone is an opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Methocarbamol is a centrally acting muscle relaxant that also causes generalized CNS depression, though its exact mechanism is not fully understood. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and methocarbamol if possible. If co-administration is necessary, initiate therapy with the lowest effective doses of both medications and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. The combination significantly impairs the ability to operate machinery or drive safely.
Mechanism
Oxycodone, an opioid agonist, and carisoprodol, a centrally acting muscle relaxant, both exert significant central nervous system (CNS) depressant effects. Carisoprodol is metabolized to meprobamate, which also possesses sedative and anxiolytic properties, further contributing to CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is deemed absolutely necessary, initiate both medications at the lowest effective doses and titrate slowly, with close monitoring for signs of CNS and respiratory depression. Educate patients on the risks and advise against driving or operating heavy machinery.
This interaction can manifest as profound sedation, respiratory depression, hypotension, and psychomotor impairment. Patients may experience dizziness, confusion, decreased level of consciousness, and impaired coordination, increasing the risk of falls and accidents.
Mechanism
Oxycodone, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Baclofen, a skeletal muscle relaxant, acts as a GABA-B receptor agonist, also causing CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided or approached with extreme caution, especially in opioid-naive patients or those with respiratory compromise. If co-administration is necessary, start with lower doses of both medications, monitor patients closely for signs of respiratory depression and excessive sedation, and educate them on the risks.
Patients may experience increased sedation, respiratory depression, dizziness, confusion, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening hypoventilation or respiratory arrest. The effects can be more pronounced in elderly patients or those with pre-existing respiratory compromise.
Mechanism
Oxycodone is an opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Tizanidine is an alpha-2 adrenergic agonist that also causes CNS depression and muscle relaxation through central mechanisms. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants if appropriate.
Patients may experience severe sedation, respiratory depression, dizziness, impaired psychomotor function, and confusion. In severe cases, this can lead to coma, respiratory arrest, and death. The impairment of motor skills can also increase the risk of falls and accidents.
Mechanism
Both oxycodone, an opioid analgesic, and metaxalone, a centrally acting muscle relaxant, exert central nervous system (CNS) depressant effects. This interaction is primarily pharmacodynamic, leading to an additive depressant effect on the brain and spinal cord. The combined action enhances GABAergic activity or reduces excitatory neurotransmission, resulting in profound CNS depression.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks, advise against operating heavy machinery or driving, and instruct them to seek immediate medical attention for severe drowsiness or difficulty breathing. Consider alternative non-opioid analgesics or non-pharmacological therapies if appropriate.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and syncope are also possible.
Mechanism
Oxycodone is an opioid agonist that primarily acts on mu-opioid receptors in the central nervous system (CNS), leading to analgesia, sedation, and respiratory depression. Chlorzoxazone is a centrally acting muscle relaxant that inhibits polysynaptic reflex arcs in the spinal cord and subcortical areas, also causing CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and chlorzoxazone if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate carefully while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating heavy machinery or driving.
This interaction can lead to severe adverse effects including profound sedation, respiratory depression, hypotension, and psychomotor impairment. Patients may experience dizziness, confusion, slowed breathing, and difficulty with coordination, increasing the risk of falls and accidental injury.
Mechanism
Oxycodone, an opioid analgesic, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and CNS depression. Orphenadrine citrate, an anticholinergic muscle relaxant, also has CNS depressant effects. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants.
The combination significantly increases the risk of severe respiratory depression, which can lead to hypoxemia, apnea, and death. Patients may experience profound sedation, somnolence, dizziness, and impaired psychomotor function. Other serious effects include coma and hypotension.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS), leading to dose-dependent CNS depression, including respiratory depression and sedation. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also causing CNS depression, sedation, and respiratory depression. The concurrent use of these two classes of drugs results in an additive and synergistic CNS depressant effect, profoundly increasing the risk of severe adverse outcomes.
Clinical Management
Co-prescription of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse events. If co-administration is absolutely necessary, it should be done with extreme caution, using the lowest effective doses for the shortest possible duration, and only if alternative treatments are inadequate. Patients and caregivers must be educated about the risks, including signs of respiratory depression and sedation, and instructed to seek immediate medical attention if these occur. Close monitoring for respiratory depression and altered mental status is crucial.
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, hypotension, and psychomotor impairment. The effects can be additive and life-threatening.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Diazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression, anxiolysis, and sedation. The synergistic CNS depressant effects of both drugs, particularly on respiratory drive, lead to a heightened risk of adverse outcomes.
Clinical Management
Coadministration should generally be avoided due to the high risk. If absolutely necessary, prescribe the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of overdose, and consider prescribing naloxone for at-risk patients.
This interaction significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may experience decreased level of consciousness, bradycardia, pinpoint pupils, and hypoxemia. The combination can also impair cognitive function and coordination, increasing the risk of falls and accidents.
Mechanism
Oxycodone, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Oxazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS activity.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse outcomes; if absolutely necessary, use the lowest effective doses for the shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, especially during initiation or dose escalation of either drug. Educate patients and caregivers about the risks and symptoms of CNS depression, and ensure naloxone is available if appropriate.
Patients may experience severe respiratory depression, characterized by decreased respiratory rate and depth, hypoxemia, and hypercapnia. Profound sedation, somnolence, dizziness, impaired psychomotor function, and hypotension are also common. In severe cases, this can progress to coma and death.
Mechanism
Both oxycodone (an opioid analgesic) and temazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly affecting the brainstem respiratory centers and consciousness. This synergistic depression significantly increases the risk of respiratory depression, profound sedation, and coma.
Clinical Management
Avoid concomitant use of oxycodone and temazepam unless the benefits outweigh the risks, and alternative treatment options are inadequate. If co-administration is necessary, prescribe the lowest effective doses and shortest durations possible, and monitor patients closely for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms, and consider prescribing naloxone for outpatient use.
The combination of oxycodone and midazolam can lead to profound sedation, respiratory depression (decreased respiratory rate and depth), coma, and death. Patients may exhibit dizziness, confusion, psychomotor impairment, and hypotension. These effects are dose-dependent and can be life-threatening.
Mechanism
Oxycodone, an opioid agonist, binds to mu-opioid receptors in the central nervous system (CNS), causing CNS depression, including respiratory depression and sedation. Midazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, further leading to CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Avoid concomitant use of oxycodone and midazolam whenever possible. If co-administration is unavoidable, use the lowest effective doses for the shortest duration possible, and monitor patients closely for respiratory depression and sedation. Consider alternative treatments that do not interact with opioids or benzodiazepines. Educate patients and caregivers about the risks and symptoms of CNS depression.
For complete prescribing information:
View full OXYCODONE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.